Mammalian Target of Rapamycin Signaling Pathways and Depression.
- Author:
Jung Goo LEE
1
;
Mi Kyong SEO
;
Sung Woo PARK
;
Young Hoon KIM
Author Information
1. Department of Psychiatry, Haeundae Paik Hospital and College of Medicine, Inje University, Busan, Korea. iybihwc@naver.com
- Publication Type:Original Article
- Keywords:
Depression;
Mammalian target of rapamycin;
N-methyl-D-asparate receptor;
Ketamine;
Pathophysiology
- MeSH:
Depression*;
Ketamine;
Neurobiology;
Sirolimus*
- From:Journal of the Korean Society of Biological Psychiatry
2016;23(1):18-23
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Depression is a complicated psychiatric illness with severe consequences. Despite recent advanced achievements of molecular neurobiology, pathophysiology of depression has not been well elucidated. Among new findings of pathophysiology of depression, the possible fast antidepressant effect by N-methyl-D-asparate receptor antagonist, such as ketamine, is regarded as a promising treatment target of depression. Ketamine stimulates the mammalian target of rapamycin (mTOR) signaling pathway and activation of mTOR signaling pathway may be a key mechanism of the antidepressant effect of ketamine. Thus, this review describes the role of mTOR signaling in the pathophysiology of depression and developing a new treatment target of depression.
